Biosimilar drugs: Current status

Current Status of Biosimilar Growth Hormone

As the first wave of biopharmaceuticals is set to expire, biosimilars or follow-on protein products (FOPPs) have emerged. The regulatory foundation for these products is more advanced and better codified in Europe than in the US. Recent approval of biosimilar Somatropin (growth hormone) in Europe and the US prompted this paper. The scientific viability of biosimilar growth hormone is reviewed. ...

Chiral Drugs: Current Status of the Industry and the Market

Chiral Drugs: Current Status of the Industry and the Market

The Current Status of New Antidiabetic Drugs

Dear Editor, Type 2 diabetes mellitus (T2DM) is a world-wide public health problem [1]. As such, the Food and Drug Administration (FDA), pharmaceutical companies and medical researchers/practitioners should be discussing the costs vs. the benefits for economically-disadvantaged populations that are disproportionately affected by T2DM and, therefore, suffering the most [2]. The current debate ab...

chiral drugs: current status of the industry and the market

0